AP NEWS

Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology

September 17, 2018

AUSTIN, Texas, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will deliver an oral presentation on AEB5100, a new human enzyme therapeutic product candidate intended to treat patients with cystinuria, at the 2018 American Society of Nephrology (ASN) being held October 23-28 in San Diego, CA.

“Consistent with Aeglea’s strategy of drug hunting in the human enzyme space, the Company is adding its third new program to our rare genetic disease therapeutic pipeline, which currently includes AEB4104 for homocystinuria along with our lead therapeutic program for Arginase 1 Deficiency, pegzilarginase,” said Anthony G. Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea.

American Society of Nephrology

Aeglea BioTherapeutics Oral Presentation Details

Date: Friday, October 26 Time: 5:54 p.m. Pacific Time Location: San Diego Convention Center, San Diego, CA Title: Enzymatic Degradation of Cystine Decreases Nephrolithiasis in a Mouse Model of Cystinuria

About Cystinase (AEB5100) in CystinuriaAEB5100 is a novel recombinant human enzyme that degrades cystine and the parent amino acid cysteine. Aeglea is developing AEB5100 for the treatment of patients with cystinuria, a rare genetic disease characterized by frequent and recurrent kidney stone formation requiring multiple procedural interventions, and by an increased risk of chronic kidney disease. Cystinuria occurs due to genetic mutations in amino acid transporters that lead to increased amounts of cystine in the urine. This results in high cystine concentrations in the urine and formation of kidney stones. Preclinical data demonstrated that AEB5100 lowered blood levels of cystine and cysteine, decreased the amount of cystine in the urine and reduced kidney stone formation in a mouse model of cystinuria.

About Aeglea BioTherapeutics Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com. Safe Harbor / Forward Looking Statements This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Media Contact: David CalusdianSharon Merrill Associates617.542.5300AGLE@investorrelations.com

Investor Contact: Joey Perrone Director, Finance & Investor RelationsAeglea BioTherapeuticsinvestors@aegleabio.com

AP RADIO
Update hourly